Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of the pharmacological effects of oridonin on hepatic ischemia/reperfusion injury in vivo

ABSTRACT: The study aims to explore the protective effects of oridonin against hepatic ischemia–reperfusion injury (IRI) and its underlying mechanisms. Hepatic IRI is a significant clinical issue that can lead to severe liver dysfunction. Oridonin (Ori), a natural diterpenoid compound, has shown promising therapeutic potential. In an in vivo model of hepatic IRI, oridonin (5 mg/kg) treatment significantly reduced serum levels of liver injury markers. In this study, we comprehensively investigated the pharmacological effects of oridonin in the treatment of liver IRI and clarified the potential molecular mechanisms.

ORGANISM(S): Mus musculus

PROVIDER: GSE302628 | GEO | 2025/10/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression signatures in oridonin-treated WT and R878H hematopoietic stem cells

Project description:Analysis of WT-Ctl v.s. WT-Ori and R878H-Ctl v.s. R878H-Ori hematopoietic stem cell (lineage-, c-kit+ Sca-1+ CD150+, CD34-). The four population of hematopoietic stem cell (HSC) were purified from the bone marrow of WT and R878H recipent mice treated with vehicle or oridonin. Results provide insight into the role of oridonin in R878H HSC.

2021-05-13 | GSE174362 | GEO

Transcriptome sequencing (RNA-Seq) of HepG2 cells upon treatment of the 10μM Oridonin or DMSO(0.1%)for exploring the metabolic mechanism of Oridonin

Project description:Oridonin is a nature diterpenoid mainly isolated from Chinese herb Rabdosia rubescens and other Isodon species. Nowadays, most of studies focused on the pharmacological effects of oridonin, the metabolism of which remains unclear. In order to investigate the effect of oridonin on metabolism-related genes, we used the second-generation transcriptome sequencing(RNA-seq) to determine the expression changes of each gene in HepG2 cells treated with oridonin.

2021-04-09 | GSE112908 | GEO

Evaluation of pharmacological effects of ginsenoside Rk2 on hepatic ischemia/reperfusion-injury in vivo and in vitro [mouse]

Project description:Hepatic ischemia-reperfusion injury (IRI) poses a significant concern in conditions such as hemorrhagic shock, hepatic resection, and liver transplantation. Recent studies have highlighted the potential of phytomedicines and natural products in effectively protecting against various forms of IRIs. In this particular investigation, we conducted high-throughput screening and identified ginsenoside Rk2 (Rk2), a rare dehydroprotopanaxadiol saponin, as a promising agent for hepatic IRI. Our subsequent in vivo and in vitro studies demonstrated that Rk2 effectively mitigated inflammation and apoptosis induced by hepatic IRI in a dose-dependent manner. In this study, we comprehensively investigate the pharmacological effects of ginsenoside Rk2 in the treatment of hepatic IRI and elucidate potential molecular mechanisms in vivo.

2024-12-20 | GSE284060 | GEO

Evaluation of pharmacological effects of ginsenoside Rk2 on hepatic ischemia/reperfusion-injury in vivo and in vitro [HuH7]

Project description:Hepatic ischemia-reperfusion injury (IRI) poses a significant concern in conditions such as hemorrhagic shock, hepatic resection, and liver transplantation. Recent studies have highlighted the potential of phytomedicines and natural products in effectively protecting against various forms of IRIs. In this particular investigation, we conducted high-throughput screening and identified ginsenoside Rk2 (RK), a rare dehydroprotopanaxadiol saponin, as a promising agent for hepatic IRI. Our subsequent in vivo and in vitro studies demonstrated that Rk2 effectively mitigated inflammation and apoptosis induced by hepatic IRI in a dose-dependent manner. In this study, we comprehensively investigate the pharmacological effects of ginsenoside Rk2 in the treatment of hepatic IRI and elucidate potential molecular mechanisms in vitro.

2024-12-20 | GSE284059 | GEO

Oridonin delays aging through AKT signaling pathway

Project description:Aging is the major risk factor for chronic diseases and disability in human. There is no effective anti-aging clinical treatment. In this study, oridonin was selected based on the drug screening strategy of Connectivity MAP (CMAP) upon transcriptomes of 102 traditional Chinese medicines (TCM) treated cell lines. Oridonin is an anti-inflammatory drug and diterpenoid isolated from Rabdosia rubescens. Oridonin exhibited a variety of pharmacological activities, including anti-tumor, antibacteria and anti-inflammation. Here, we found that oridonin inhibited cellular senescence in human diploid fibroblasts (2BS and WI-38), indicated by decreased senescence-associated β-galactosidase (SA-β-gal) staining. Compared with the elderly control group, the positive cell rate in the oridonin intervention group was 48.5%, and the cell shape was similar to young cells. Oridonin prolonged the lifespan of yeast by 14.6%~48.9%, and prolonged the average life span of naturally aged mice by 21.6%. It also increased the healthspan of aged mice. In addition, oridonin also improved doxorubicin-induced cellular senescence and mouse senescence. Compared with the model group, the percentage of SA-β-gal positive cells in the oridonin treatment group was reduced to 59.8%. It prolonged the average life span of mice by 53.8% as well as the healthspan. Mechanistically, we show that oridonin delayed aging through the AKT signaling pathways and reverses the genetic changes caused by doxorubicin-induced cell senescence. Therefore, oridonin may be an ideal candidate for the development of anti-aging drugs, and it also provides therapeutic potential in other diseases.

2022-03-18 | GSE189789 | GEO

Evaluation of the pharmacological effects of oridonin on hepatic ischemia/reperfusion injury in vivo

Project description:Evaluation of the pharmacological effects of oridonin on hepatic ischemia/reperfusion injury in vivo

| PRJNA1291617 | ENA

Identification of proteins interacting with cytoplasmic high-mobility group box 1 (HMGB1) during the hepatocellular response to ischemia reperfusion injury

Project description:Ischemia/reperfusion injury (IRI) occurs in liver transplantations and major resections and can lead to liver dysfunction. HMGB1 locates in nucleus of normal hepatocytes, but translocates to cytoplasm and the extracellular space during IRI. Although the functions of nuclear and extracellular HMGB1 are well explored, the role cytoplasmic HMGB1 plays in hepatic IRI is still unknown. We hypothesize cytoplasmic HMGB1 interacts with binding proteins involved in the hepatocellular response to IRI. In this study binding proteins of cytoplasmic HMGB1 during hepatic IRI were identified. Normal and warm ischemia reperfusion (WI/R) liver tissues were used for cytoplasmic protein extraction. The protein extracts were subjected to co-immunoprecipitation to enrich HMGB1-protein complexes. To identify the immunoprecipitated proteins in eluates, 2DE and subsequent MS detection were performed. Three identified proteins were verified using western blotting: betaine--homocysteine S-methyltransferase 1 (BHMT), cystathionine gamma-lyase (CTH) and ATP synthase beta subunit (ATP5B). All three identified proteins have a role in metabolic pathways and autophagy. Our results demonstrate cytoplasmic HMGB1 binds to BHMT, CTH and ATP5B during hepatic WI/R. Since both, cytoplasmic HMGB1 and binding proteins, are involved in autophagy, we speculate this protein complex may be involved in the hepatocellular response to IRI via the autophagy pathway.

2017-03-10 | PXD003538 | Pride

Transcriptomics of Human Liver Ischemia and Reperfusion Injury

Project description:For orthotopic liver transplants, ischemia-reperfusion injury (IRI) is known to compromise allograft survival. To better understand the transcriptomics of immune responses underlying liver transplant IRI, RNA-seq was performed on liver biopsies from 23 IRI+ and 17 IRI- patients, both pre-transplant and post-transplant. Genes that are differentially expressed in IRI+ samples, along with the pathways enriched for by those genes, were identified.

2020-08-07 | GSE151648 | GEO

FGF18 alleviates hepatic ischemia-reperfusion injury via the USP16-mediated KEAP1/Nrf2 signaling pathway in male mice

Project description:Hepatic ischemia-reperfusion injury (IRI) is a common complication occurs during hepatic resection and transplantation. However, the mechanisms underlying hepatic IRI have not been fully elucidated. Here, we aim to explore the role of fibroblast growth factor 18 (FGF18) in hepatic IRI. In this work, we find that Hepatic stellate cells (HSCs) secrete FGF18 and alleviates hepatocytes injury. HSCs-specific FGF18 deletion largely aggravates hepatic IRI. Mechanistically, FGF18 treatment reduces the levels of ubiquitin carboxyl-terminal hydrolase 16 (USP16), leading to increased ubiquitination levels of Kelch Like ECH Associated Protein 1 (KEAP1) and the activation of nuclear factor erythroid 2-related factor 2 (Nrf2). Furthermore, USP16 interacts and deubiquitinates KEAP1. More importantly, Nrf2 directly binds to the promoter of USP16 and forms a negative feedback loop with USP16. Collectively, our results show FGF18 alleviates hepatic IRI by USP16/KEAP1/Nrf2 signaling pathway in male mice, suggesting that FGF18 represents a promising therapeutic approach for hepatic IRI.

2023-09-05 | GSE242032 | GEO

Transplantation of human hepatic organoids rescues liver ischemic reperfusion injury in immune-deficient mice

Project description:The effectiveness and underlying mechanisms of organoid transplantation therapy in liver ischemia-reperfusion injury (IRI) remain underexplored. We aimed to investigate the therapeutic potential and biological processes of human adult stem cells (hASCs)-derived hepatic organoids (hHOs) in treating liver IRI in an immune-deficient murine model.

2024-05-13 | PXD052240 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data